It teaches us to buy into Co's that have money in the bank! By the extremeness of this R/S, something may be up? There is a good portfolio of therapies and Immunization vaccines, so maybe a buyout is in the works? But even then, we'd be lucky to get 50% of our money back! Koos is desperate, so maybe the buyout Vultures are honing-in on the weak?
There will be a new opportunity to make money here. Any current shareholders need to sell now for whatever they can get. Then wait for the R/S in March. There is no question the R/S was done to dilute, so the remaining 3 million shares in the SS is a place to build on. I expect a minimum of 500 -800 million shares diluted, with nothing pumped to stop a decline in the share price. Price should settle around .10-.20. Buy back then.